|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leemans CR, Snijders PJF and Brakenhoff
RH: The molecular landscape of head and neck cancer. Nat Rev
Cancer. 18:269–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Research Network, .
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Puram SV, Mints M, Pal A, Qi Z, Reeb A,
Gelev K, Barrett TF, Gerndt S, Liu P, Parikh AS, et al: Cellular
states are coupled to genomic and viral heterogeneity in
HPV-related oropharyngeal carcinoma. Nat Genet. 55:640–650. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnson DE, Burtness B, Leemans CR, Lui
VWY, Bauman JE and Grandis JR: Head and neck squamous cell
carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fouad S, Hauton D and D'Angiolella V:
E2F1: Cause and consequence of DNA replication stress. Front Mol
Biosci. 7:5993322021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin M, Ji X, Lv Y, Cui D and Xie J: The
roles of TRAF3 in immune responses. Dis Markers. 2023:77878032023.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hornick EL and Bishop GA: TRAF3: Guardian
of T lymphocyte functions. Front Immunol. 14:11292512023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seiwert TY, Zuo Z, Keck MK, Khattri A,
Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, et
al: Integrative and comparative genomic analysis of HPV-positive
and HPV-negative head and neck squamous cell carcinomas. Clin
Cancer Res. 21:632–641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Häfner N, Driesch C, Gajda M, Jansen L,
Kirchmayr R, Runnebaum IB and Dürst M: Integration of the HPV16
genome does not invariably result in high levels of viral oncogene
transcripts. Oncogene. 27:1610–1617. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parfenov M, Pedamallu CS, Gehlenborg N,
Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova
EV, Wilkerson MD, et al: Characterization of HPV and host genome
interactions in primary head and neck cancers. Proc Natl Acad Sci
USA. 111:15544–15549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hettmann A, Demcsák A, Decsi G, Bach Á,
Pálinkó D, Rovó L, Nagy K, Takács M and Minarovits J: Infectious
agents associated with head and neck carcinomas. Adv Exp Med Biol.
897:63–80. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bai X, Cui C, Yin J, Li H, Gong Q, Wei B
and Lu Y: The association between oral hygiene and head and neck
cancer: A meta-analysis. Acta Odontol Scand. 81:374–395. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kitamura N, Sento S, Yoshizawa Y, Sasabe
E, Kudo Y and Yamamoto T: Current trends and future prospects of
molecular targeted therapy in head and neck squamous cell
carcinoma. Int J Mol Sci. 22:2402020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Forman R, Deshpande H, Burtness B and
Bhatia AK: Efficacy and toxicity of weekly paclitaxel, carboplatin,
and cetuximab as induction chemotherapy or in cases of metastases
or relapse for head and neck cancer with a focus on elderly or
frail patients. Head Neck. 44:1777–1786. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dokala A and Thakur SS: Extracellular
region of epidermal growth factor receptor: A potential target for
anti-EGFR drug discovery. Oncogene. 36:2337–2344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eze N, Lee JW, Yang DH, Zhu F, Neumeister
V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH
and Burtness B: PTEN loss is associated with resistance to
cetuximab in patients with head and neck squamous cell carcinoma.
Oral Oncol. 91:69–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Emran TB, Shahriar A, Mahmud AR, Rahman T,
Abir MH, Siddiquee MF, Ahmed H, Rahman N, Nainu F, Wahyudin E, et
al: Multidrug resistance in cancer: Understanding molecular
mechanisms, immunoprevention and therapeutic approaches. Front
Oncol. 12:8916522022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giddings EL, Champagne DP, Wu MH, Laffin
JM, Thornton TM, Valenca-Pereira F, Culp-Hill R, Fortner KA, Romero
N, East J, et al: Mitochondrial ATP fuels ABC transporter-mediated
drug efflux in cancer chemoresistance. Nat Commun. 12:28042021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ming H, Li B, Jiang J, Qin S, Nice EC, He
W, Lang T and Huang C: Protein degradation: Expanding the toolbox
to restrain cancer drug resistance. J Hematol Oncol. 16:62023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang N, Ma T and Yu B: Targeting
epigenetic regulators to overcome drug resistance in cancers.
Signal Transduct Target Ther. 8:692023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su S, Chen J, Yao H, Liu J, Yu S, Lao L,
Wang M, Luo M, Xing Y, Chen F, et al:
CD10+GPR77+ cancer-associated fibroblasts
promote cancer formation and chemoresistance by sustaining cancer
stemness. Cell. 172:841–856.e16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ito Y, Tazaki G, Kondo Y, Takahashi G and
Sakamaki F: Therapeutic effect of nintedanib on acute exacerbation
of interstitial lung diseases. Respir Med Case Rep. 26:317–320.
2019.PubMed/NCBI
|
|
25
|
Hui L and Chen Y: Tumor microenvironment:
Sanctuary of the devil. Cancer Lett. 368:7–13. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
da Cunha BR, Domingos C, Stefanini ACB,
Henrique T, Polachini GM, Castelo-Branco P and Tajara EH: Cellular
interactions in the tumor microenvironment: The role of secretome.
J Cancer. 10:4574–4587. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nia HT, Munn LL and Jain RK: Physical
traits of cancer. Science. 370:eaaz08682020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gourmet LE and Walker-Samuel S: The role
of physics in multiomics and cancer evolution. Front Oncol.
13:10680532023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stratton MR, Campbell PJ and Futreal PA:
The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vendramin R, Litchfield K and Swanton C:
Cancer evolution: Darwin and beyond. EMBO J. 40:e1083892021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nowell PC: The clonal evolution of tumor
cell populations. Science. 194:23–28. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dexter DL, Kowalski HM, Blazar BA, Fligiel
Z, Vogel R and Heppner GH: Heterogeneity of tumor cells from a
single mouse mammary tumor. Cancer Res. 38:3174–3181.
1978.PubMed/NCBI
|
|
36
|
Greaves M and Maley CC: Clonal evolution
in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Swanton C: Intratumor heterogeneity:
Evolution through space and time. Cancer Res. 72:4875–4882. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Williams MJ, Werner B, Barnes CP, Graham
TA and Sottoriva A: Identification of neutral tumor evolution
across cancer types. Nat Genet. 48:238–244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mohan M and Jagannathan N: Oral field
cancerization: An update on current concepts. Oncol Rev.
8:2442014.PubMed/NCBI
|
|
40
|
Shen X, Song S, Li C and Zhang J:
Synonymous mutations in representative yeast genes are mostly
strongly non-neutral. Nature. 606:725–731. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kristofich J, Morgenthaler AB, Kinney WR,
Ebmeier CC, Snyder DJ, Old WM, Cooper VS and Copley SD: Synonymous
mutations make dramatic contributions to fitness when growth is
limited by a weak-link enzyme. PLoS Genet. 14:e10076152018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li R, Dong J, Zhang H, Zhao Q, Li X, Liu
X, Ye Y, Deng S, Lin D, Zheng J and Zuo Z: Clinical and genomic
characterization of neutral tumor evolution in head and neck
squamous cell carcinoma. Genomics. 112:3448–3454. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cortés-Ciriano I, Lee JJ, Xi R, Jain D,
Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS, et
al: Comprehensive analysis of chromothripsis in 2,658 human cancers
using whole-genome sequencing. Nat Genet. 52:331–341. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Voronina N, Wong JKL, Hübschmann D,
Hlevnjak M, Uhrig S, Heilig CE, Horak P, Kreutzfeldt S, Mock A,
Stenzinger A, et al: The landscape of chromothripsis across adult
cancer types. Nat Commun. 11:23202020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shen MM: Chromoplexy: A new category of
complex rearrangements in the cancer genome. Cancer Cell.
23:567–569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Baca SC, Prandi D, Lawrence MS, Mosquera
JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi
M, et al: Punctuated evolution of prostate cancer genomes. Cell.
153:666–677. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sottoriva A, Kang H, Ma Z, Graham TA,
Salomon MP, Zhao J, Marjoram P, Siegmund K, Press MF, Shibata D and
Curtis C: A Big Bang model of human colorectal tumor growth. Nat
Genet. 47:209–216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sottoriva A, Barnes CP and Graham TA:
Catch my drift? Making sense of genomic intra-tumour heterogeneity.
Biochim Biophys Acta Rev Cancer. 1867:95–100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Niida A, Mimori K, Shibata T and Miyano S:
Modeling colorectal cancer evolution. J Hum Genet. 66:869–878.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Laukien FH: The evolution of evolutionary
processes in organismal and cancer evolution. Prog Biophys Mol
Biol. 165:43–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Caravagna G, Giarratano Y, Ramazzotti D,
Tomlinson I, Graham TA, Sanguinetti G and Sottoriva A: Detecting
repeated cancer evolution from multi-region tumor sequencing data.
Nat Methods. 15:707–714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
McGranahan N and Swanton C: Clonal
heterogeneity and tumor evolution: Past, present, and the future.
Cell. 168:613–628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Niida A, Iwasaki WM and Innan H: Neutral
theory in cancer cell population genetics. Mol Biol Evol.
35:1316–1321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Martínez-Jiménez F, Movasati A, Brunner
SR, Nguyen L, Priestley P, Cuppen E and Van Hoeck A: Pan-cancer
whole-genome comparison of primary and metastatic solid tumours.
Nature. 618:333–341. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nguyen B, Fong C, Luthra A, Smith SA,
DiNatale RG, Nandakumar S, Walch H, Chatila WK, Madupuri R, Kundra
R, et al: Genomic characterization of metastatic patterns from
prospective clinical sequencing of 25,000 patients. Cell.
185:563–575.e11. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhao M, Liu Y, Zheng C and Qu H: dbEMT
2.0: An updated database for epithelial-mesenchymal transition
genes with experimentally verified information and precalculated
regulation information for cancer metastasis. J Genet Genomics.
46:595–597. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Acar A, Nichol D, Fernandez-Mateos J,
Cresswell GD, Barozzi I, Hong SP, Trahearn N, Spiteri I, Stubbs M,
Burke R, et al: Exploiting evolutionary steering to induce
collateral drug sensitivity in cancer. Nat Commun. 11:19232020.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tarabichi M, Martincorena I, Gerstung M,
Leroi AM, Markowetz F; PCAWG Evolution and Heterogeneity Working
Group and Spellman PT, ; Morris QD, Lingjærde OC, Wedge DC and Van
Loo P: Neutral tumor evolution? Nat Genet. 50:1630–1633. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Persi E, Wolf YI, Horn D, Ruppin E,
Demichelis F, Gatenby RA, Gillies RJ and Koonin EV:
Mutation-selection balance and compensatory mechanisms in tumour
evolution. Nat Rev Genet. 22:251–262. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Marine JC, Dawson SJ and Dawson MA:
Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev
Cancer. 20:743–756. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Taube JH, Herschkowitz JI, Komurov K, Zhou
AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, et
al: Core epithelial-to-mesenchymal transition interactome
gene-expression signature is associated with claudin-low and
metaplastic breast cancer subtypes. Proc Natl Acad Sci USA.
107:15449–15454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Graves CA, Abboodi FF, Tomar S, Wells J
and Pirisi L: The translational significance of
epithelial-mesenchymal transition in head and neck cancer. Clin
Transl Med. 3:602014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Puram SV, Tirosh I, Parikh AS, Patel AP,
Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, et
al: Single-cell transcriptomic analysis of primary and metastatic
tumor ecosystems in head and neck cancer. Cell. 171:1611–1624.e24.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Pavón MA, Arroyo-Solera I, León X,
Téllez-Gabriel M, Virós D, Gallardo A, Céspedes MV, Casanova I,
Lopez-Pousa A, Barnadas A, et al: The combined use of EFS, GPX2,
and SPRR1A expression could distinguish favorable from poor
clinical outcome among epithelial-like head and neck carcinoma
subtypes. Head Neck. 41:1830–1845. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
DeCamp SJ, Tsuda VMK, Ferruzzi J, Koehler
SA, Giblin JT, Roblyer D, Zaman MH, Weiss ST, Kılıç A, De Marzio M,
et al: Epithelial layer unjamming shifts energy metabolism toward
glycolysis. Sci Rep. 10:183022020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
De Marzio M, Kılıç A, Maiorino E, Mitchel
JA, Mwase C, O'Sullivan MJ, McGill M, Chase R, Fredberg JJ, Park
JA, et al: Genomic signatures of the unjamming transition in
compressed human bronchial epithelial cells. Sci Adv.
7:eabf10882021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kılıç A, Ameli A, Park JA, Kho AT,
Tantisira K, Santolini M, Cheng F, Mitchel JA, McGill M, O'Sullivan
MJ, et al: Mechanical forces induce an asthma gene signature in
healthy airway epithelial cells. Sci Rep. 10:9662020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ataie-Kachoie P, Pourgholami MH,
Richardson DR and Morris DL: Gene of the month: Interleukin 6
(IL-6). J Clin Pathol. 67:932–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Taher MY, Davies DM and Maher J: The role
of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc
Trans. 46:1449–1462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wu Y and Zhou BP:
TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and
invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li Y, Azmi AS and Mohammad RM: Deregulated
transcription factors and poor clinical outcomes in cancer
patients. Semin Cancer Biol. 86:122–134. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Xin W, Zhao C, Jiang L, Pei D, Zhao L and
Zhang C: Identification of a novel epithelial-mesenchymal
transition gene signature predicting survival in patients with
HNSCC. Pathol Oncol Res. 27:5851922021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Vallina C, López-Pintor RM,
González-Serrano J, de Vicente JC, Hernández G and Lorz C: Genes
involved in the epithelial-mesenchymal transition in oral cancer: A
systematic review. Oral Oncol. 117:1053102021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Okuyama K, Suzuki K and Yanamoto S:
Relationship between tumor budding and partial
epithelial-mesenchymal transition in head and neck cancer. Cancers
(Basel). 15:11112023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tamimi A, Tamimi A, Sorkheh F, Asl SM,
Ghafari A, Karimi AG, Erabi G, Pourmontaseri H and Deravi N:
Monoclonal antibodies for the treatment of squamous cell carcinoma:
A literature review. Cancer Rep (Hoboken). 6:e18022023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Byeon HK, Ku M and Yang J: Beyond EGFR
inhibition: Multilateral combat strategies to stop the progression
of head and neck cancer. Exp Mol Med. 51:1–14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Klein P, Mattoon D, Lemmon MA and
Schlessinger J: A structure-based model for ligand binding and
dimerization of EGF receptors. Proc Natl Acad Sci USA. 101:929–934.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Nair S, Trummell HQ, Rajbhandari R, Thudi
NK, Nozell SE, Warram JM, Willey CD, Yang ES, Placzek WJ, Bonner JA
and Bredel M: Novel EGFR ectodomain mutations associated with
ligand-independent activation and cetuximab resistance in head and
neck cancer. PLoS One. 15:e02290772020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Purba ER, Saita EI and Maruyama IN:
Activation of the EGF receptor by ligand binding and oncogenic
mutations: The ‘rotation model’. Cells. 6:132017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kriegs M, Clauditz TS, Hoffer K, Bartels
J, Buhs S, Gerull H, Zech HB, Bußmann L, Struve N, Rieckmann T, et
al: Analyzing expression and phosphorylation of the EGF receptor in
HNSCC. Sci Rep. 9:135642019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kalyankrishna S and Grandis JR: Epidermal
growth factor receptor biology in head and neck cancer. J Clin
Oncol. 24:2666–2672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Najafi M, Ahmadi A and Mortezaee K:
Extracellular-signal-regulated kinase/mitogen-activated protein
kinase signaling as a target for cancer therapy: An updated review.
Cell Biol Int. 43:1206–1222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Nishihara S, Yamaoka T, Ishikawa F,
Higuchi K, Hasebe Y, Manabe R, Kishino Y, Kusumoto S, Ando K,
Kuroda Y, et al: Mechanisms of EGFR-TKI-induced apoptosis and
strategies targeting apoptosis in EGFR-mutated non-small cell lung
cancer. Genes (Basel). 13:21832022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Liu X, Mei W, Zhang P and Zeng C: PIK3CA
mutation as an acquired resistance driver to EGFR-TKIs in non-small
cell lung cancer: Clinical challenges and opportunities. Pharmacol
Res. 202:1071232024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lai SY and Johnson FM: Defining the role
of the JAK-STAT pathway in head and neck and thoracic malignancies:
Implications for future therapeutic approaches. Drug Resist Updat.
13:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Li L, Ji S, Shrestha C, Jiang Y, Liao L,
Xu F, Liu Z, Bikle DD and Xie Z: p120-catenin suppresses
proliferation and tumor growth of oral squamous cell carcinoma via
inhibiting nuclear phospholipase C-γ1 signaling. J Cell Physiol.
235:9399–9413. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Mittal S, Kamath A, Joseph AM and Rajala
MS: PLCγ1-dependent invasion and migration of cells expressing
NSCLC-associated EGFR mutants. Int J Oncol. 57:989–1000.
2020.PubMed/NCBI
|
|
94
|
Li Q, Tie Y, Alu A, Ma X and Shi H:
Targeted therapy for head and neck cancer: Signaling pathways and
clinical studies. Signal Transduct Target Ther. 8:312023.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Silva-Oliveira RJ, Melendez M, Martinho O,
Zanon MF, de Souza Viana L, Carvalho AL and Reis RM: AKT can
modulate the in vitro response of HNSCC cells to irreversible EGFR
inhibitors. Oncotarget. 8:53288–53301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kordbacheh F and Farah CS: Current and
emerging molecular therapies for head and neck squamous cell
carcinoma. Cancers (Basel). 13:54712021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ebrahimi N, Fardi E, Ghaderi H, Palizdar
S, Khorram R, Vafadar R, Ghanaatian M, Rezaei-Tazangi F, Baziyar P,
Ahmadi A, et al: Receptor tyrosine kinase inhibitors in cancer.
Cell Mol Life Sci. 80:1042023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Lacas B, Carmel A, Landais C, Wong SJ,
Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, et al:
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An
update on 107 randomized trials and 19,805 patients, on behalf of
MACH-NC group. Radiother Oncol. 156:281–293. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Guigay J, Aupérin A, Fayette J,
Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L,
Capitain O, Cupissol D, et al: Cetuximab, docetaxel, and cisplatin
versus platinum, fluorouracil, and cetuximab as first-line
treatment in patients with recurrent or metastatic head and neck
squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): A multicentre,
open-label, randomised, phase 2 trial. Lancet Oncol. 22:463–475.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Eggers H, Häbel L, Ganser A, Grünwald V,
Merten R, Warnecke A, Durisin M and Ivanyi P: Anti-EGFR-based
therapy in recurrent or metastatic HNSCC-what difference does it
make? Cancer Invest. 41:93–100. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Rich TA, Shepard RC and Mosley ST: Four
decades of continuing innovation with fluorouracil: Current and
future approaches to fluorouracil chemoradiation therapy. J Clin
Oncol. 22:2214–2232. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Muraro E, Fanetti G, Lupato V, Giacomarra
V, Steffan A, Gobitti C, Vaccher E and Franchin G: Cetuximab in
locally advanced head and neck squamous cell carcinoma: Biological
mechanisms involved in efficacy, toxicity and resistance. Crit Rev
Oncol Hematol. 164:1034242021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Okada Y, Kimura T, Nakagawa T, Okamoto K,
Fukuya A, Goji T, Fujimoto S, Sogabe M, Miyamoto H, Muguruma N, et
al: EGFR downregulation after Anti-EGFR therapy predicts the
antitumor effect in colorectal cancer. Mol Cancer Res.
15:1445–1454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Kang JJ, Ko A, Kil SH, Mallen-St Clair J,
Shin DS, Wang MB and Srivatsan ES: EGFR pathway targeting drugs in
head and neck cancer in the era of immunotherapy. Biochim Biophys
Acta Rev Cancer. 1878:1888272023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Chaudhary R, Slebos RJC, Noel LC, Song F,
Poole MI, Hoening DS, Hernandez-Prera JC, Conejo-Garcia JR,
Guevara-Patino JA, Wang X, et al: EGFR inhibition by cetuximab
modulates hypoxia and IFN response genes in head and neck squamous
cell carcinoma. Cancer Res Commun. 3:896–907. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino
JE, Toettcher JE, Bivona TG and Lim WA: Cancer mutations and
targeted drugs can disrupt dynamic signal encoding by the Ras-Erk
pathway. Science. 361:eaao30482018. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Jie HB, Schuler PJ, Lee SC, Srivastava RM,
Argiris A, Ferrone S, Whiteside TL and Ferris RL: CTLA-4+
regulatory T cells increased in cetuximab-treated head and neck
cancer patients suppress NK cell cytotoxicity and correlate with
poor prognosis. Cancer Res. 75:2200–2210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Kagohara LT, Zamuner F, Davis-Marcisak EF,
Sharma G, Considine M, Allen J, Yegnasubramanian S, Gaykalova DA
and Fertig EJ: Integrated single-cell and bulk gene expression and
ATAC-seq reveals heterogeneity and early changes in pathways
associated with resistance to cetuximab in HNSCC-sensitive cell
lines. Br J Cancer. 123:101–113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ryman JT and Meibohm B: Pharmacokinetics
of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol.
6:576–588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Tathineni P, Joshi N and Jelinek MJ:
Current state and future directions of EGFR-directed therapy in
head and neck cancer. Curr Treat Options Oncol. 24:680–692. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
de Castro G Jr, Alves GV, Castro AF,
Chaves ALF, De Marchi P, de Oliveira TB, Dias FL, Guindalini RSC,
Nicolau UR, Soares A and Mora PAR: Criteria for eligibility to
cisplatin in the curative treatment of head and neck cancer:
Consensus opinion from a panel of experts. Crit Rev Oncol Hematol.
131:30–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Carinato H, Burgy M, Ferry R, Fischbach C,
Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, et
al: Weekly paclitaxel, carboplatin, and cetuximab as first-line
treatment of recurrent and/or metastatic head and neck squamous
cell carcinoma for patients ineligible to cisplatin-based
chemotherapy: A retrospective monocentric study in 60 patients.
Front Oncol. 11:7145512021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Abdulla M, Belal AA, Sakr A, El Arab LE,
Mokhtar M, Allahloubi N, Ghali R, Hashem T and Arafat W:
Eligibility criteria to cisplatin in head and neck squamous cell
carcinoma: Egyptian expert opinion. Health Sci Rep. 6:e10372023.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Guigay J, Fayette J, Dillies AF, Sire C,
Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec
Le Moal L, et al: Cetuximab, docetaxel, and cisplatin as first-line
treatment in patients with recurrent or metastatic head and neck
squamous cell carcinoma: A multicenter, phase II GORTEC study. Ann
Oncol. 26:1941–1947. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mehanna H, Robinson M, Hartley A, Kong A,
Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, et
al: Radiotherapy plus cisplatin or cetuximab in low-risk human
papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An
open-label randomised controlled phase 3 trial. Lancet. 393:51–60.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Silver JA, Turkdogan S, Roy CF,
Subramaniam T, Henry M and Sadeghi N: De-escalation strategies for
human papillomavirus-associated oropharyngeal squamous cell
carcinoma-where are we now? Curr Oncol. 29:3668–3697. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Willey CD, Anderson JC, Trummell HQ, Naji
F, de Wijn R, Yang ES, Bredel M, Thudi NK and Bonner JA:
Differential escape mechanisms in cetuximab-resistant head and neck
cancer cells. Biochem Biophys Res Commun. 517:36–42. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Yonesaka K, Tanaka K, Kitano M, Kawakami
H, Hayashi H, Takeda M, Sakai K, Nishio K, Doi K and Nakagawa K:
Aberrant HER3 ligand heregulin-expressing head and neck squamous
cell carcinoma is resistant to anti-EGFR antibody cetuximab, but
not second-generation EGFR-TKI. Oncogenesis. 8:542019. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Picon H and Guddati AK: Mechanisms of
resistance in head and neck cancer. Am J Cancer Res. 10:2742–2751.
2020.PubMed/NCBI
|
|
122
|
Ortiz-Cuaran S, Bouaoud J, Karabajakian A,
Fayette J and Saintigny P: Precision medicine approaches to
overcome resistance to therapy in head and neck cancers. Front
Oncol. 11:6143322021. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Cheng H, Fertig EJ, Ozawa H, Hatakeyama H,
Howard JD, Perez J, Considine M, Thakar M, Ranaweera R, Krigsfeld G
and Chung CH: Decreased SMAD4 expression is associated with
induction of epithelial-to-mesenchymal transition and cetuximab
resistance in head and neck squamous cell carcinoma. Cancer Biol
Ther. 16:1252–1258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Boeckx C, Blockx L, Op de Beeck K, Limame
R, Camp GV, Peeters M, Vermorken JB, Specenier P, Wouters A, Baay M
and Lardon F: Establishment and characterization of cetuximab
resistant head and neck squamous cell carcinoma cell lines: Focus
on the contribution of the AP-1 transcription factor. Am J Cancer
Res. 5:1921–1938. 2015.PubMed/NCBI
|
|
125
|
Citron F, Segatto I, Musco L, Pellarin I,
Rampioni Vinciguerra GL, Franchin G, Fanetti G, Miccichè F,
Giacomarra V, Lupato V, et al: miR-9 modulates and predicts the
response to radiotherapy and EGFR inhibition in HNSCC. EMBO Mol
Med. 13:e128722021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Morvan VL, Richard É, Cadars M, Fessart D,
Broca-Brisson L, Auzanneau C, Pasquies A, Modesto A, Lusque A,
Mathoulin-Pélissier S, et al: Cytochrome P450 1B1 polymorphism
drives cancer cell stemness and patient outcome in head-and-neck
carcinoma. Br J Cancer. 123:772–784. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Wheeler DL, Huang S, Kruser TJ,
Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and
Harari PM: Mechanisms of acquired resistance to cetuximab: Role of
HER (ErbB) family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Nelhűbel GA, Cserepes M, Szabó B, Türk D,
Kárpáti A, Kenessey I, Rásó E, Barbai T, Hegedűs Z, László V, et
al: EGFR alterations influence the cetuximab treatment response and
c-MET tyrosine-kinase inhibitor sensitivity in experimental head
and neck squamous cell carcinomas. Pathol Oncol Res. 27:6202562021.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan
C, Wu Y, Li X, Li X, Li G, et al: Function of the c-Met receptor
tyrosine kinase in carcinogenesis and associated therapeutic
opportunities. Mol Cancer. 17:452018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Cortesina G, Martone T, Galeazzi E,
Olivero M, De Stefani A, Bussi M, Valente G, Comoglio PM and Di
Renzo MF: Staging of head and neck squamous cell carcinoma using
the MET oncogene product as marker of tumor cells in lymph node
metastases. Int J Cancer. 89:286–292. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Slomiany MG, Black LA, Kibbey MM, Tingler
MA, Day TA and Rosenzweig SA: Insulin-like growth factor-1 receptor
and ligand targeting in head and neck squamous cell carcinoma.
Cancer Lett. 248:269–279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Gonzales CB, De La Chapa JJ, Saikumar P,
Singha PK, Dybdal-Hargreaves NF, Chavez J, Horning AM, Parra J and
Kirma NB: Co-targeting ALK and EGFR parallel signaling in oral
squamous cell carcinoma. Oral Oncol. 59:12–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Iyer G, Price J, Bourgeois S, Armstrong E,
Huang S and Harari PM: Insulin-like growth factor 1 receptor
mediated tyrosine 845 phosphorylation of epidermal growth factor
receptor in the presence of monoclonal antibody cetuximab. BMC
Cancer. 16:7732016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Krumbach R, Schüler J, Hofmann M,
Giesemann T, Fiebig HH and Beckers T: Primary resistance to
cetuximab in a panel of patient-derived tumour xenograft models:
Activation of MET as one mechanism for drug resistance. Eur J
Cancer. 47:1231–1243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Ouyang X, Barling A, Lesch A, Tyner JW,
Choonoo G, Zheng C, Jeng S, West TM, Clayburgh D, Courtneidge SA,
et al: Induction of anaplastic lymphoma kinase (ALK) as a novel
mechanism of EGFR inhibitor resistance in head and neck squamous
cell carcinoma patient-derived models. Cancer Biol Ther.
19:921–933. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Umemori K, Ono K, Eguchi T, Kawai H,
Nakamura T, Ogawa T, Yoshida K, Kanemoto H, Sato K, Obata K, et al:
EpEX, the soluble extracellular domain of EpCAM, resists cetuximab
treatment of EGFR-high head and neck squamous cell carcinoma. Oral
Oncol. 142:1064332023. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Gires O, Pan M, Schinke H, Canis M and
Baeuerle PA: Expression and function of epithelial cell adhesion
molecule EpCAM: Where are we after 40 years? Cancer Metastasis Rev.
39:969–987. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Went PT, Lugli A, Meier S, Bundi M,
Mirlacher M, Sauter G and Dirnhofer S: Frequent EpCam protein
expression in human carcinomas. Hum Pathol. 35:122–128. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Mignion L, Acciardo S, Gourgue F, Joudiou
N, Caignet X, Goebbels RM, Corbet C, Feron O, Bouzin C, Cani PD, et
al: Metabolic imaging using hyperpolarized pyruvate-lactate
exchange assesses response or resistance to the EGFR inhibitor
cetuximab in patient-derived HNSCC xenografts. Clin Cancer Res.
26:1932–1943. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Bae T, Hallis SP and Kwak MK: Hypoxia,
oxidative stress, and the interplay of HIFs and NRF2 signaling in
cancer. Exp Mol Med. 56:501–514. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Deng L, Wang L, Zhang J, Zhao L, Meng Y,
Zheng J, Xu W, Zhu Z and Huang H: The mechanism of action and
biodistribution of a novel EGFR/VEGF bispecific fusion protein that
exhibited superior antitumor activities. Heliyon. 9:e169222023.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Liang W, Zheng Y, Zhang J and Sun X:
Multiscale modeling reveals angiogenesis-induced drug resistance in
brain tumors and predicts a synergistic drug combination targeting
EGFR and VEGFR pathways. BMC Bioinformatics. 20 (Suppl 7):S2032019.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Wiechec E, Hansson KT, Alexandersson L,
Jönsson JI and Roberg K: Hypoxia mediates differential response to
anti-EGFR therapy in HNSCC cells. Int J Mol Sci. 18:9432017.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Ge H, Ferris RL and Wang JH: Cetuximab
responses in patients with HNSCC correlate to clonal expansion
feature of peripheral and tumor-infiltrating T cells with Top
T-cell receptor clonotypes. Clin Cancer Res. 29:647–658. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Parikh AS, Yu VX, Flashner S, Okolo OB, Lu
C, Henick BS, Momen-Heravi F, Puram SV, Teknos T, Pan Q and
Nakagawa H: Patient-derived three-dimensional culture techniques
model tumor heterogeneity in head and neck cancer. Oral Oncol.
138:1063302023. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Cree IA and Charlton P: Molecular chess?
Hallmarks of anti-cancer drug resistance. BMC Cancer. 17:102017.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Shirani-Bidabadi S, Tabatabaee A, Tavazohi
N, Hariri A, Aref AR, Zarrabi A, Casarcia N, Bishayee A and Mirian
M: CRISPR technology: A versatile tool to model, screen, and
reverse drug resistance in cancer. Eur J Cell Biol. 102:1512992023.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Liu S, Wang R and Fang J: Exploring the
frontiers: Tumor immune microenvironment and immunotherapy in head
and neck squamous cell carcinoma. Discov Oncol. 15:222024.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Jin Y, Huang Y, Ren H, Huang H, Lai C,
Wang W, Tong Z, Zhang H, Wu W, Liu C, et al: Nano-enhanced
immunotherapy: Targeting the immunosuppressive tumor
microenvironment. Biomaterials. 305:1224632024. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Avgoustakis K and Angelopoulou A:
Biomaterial-based responsive nanomedicines for targeting solid
tumor microenvironments. Pharmaceutics. 16:1792024. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Harrer DC, Lüke F, Pukrop T, Ghibelli L,
Reichle A and Heudobler D: Addressing genetic tumor heterogeneity,
post-therapy metastatic spread, cancer repopulation, and
development of acquired tumor cell resistance. Cancers (Basel).
16:1802023. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Derbal Y: Cell adaptive fitness and cancer
evolutionary dynamics. Cancer Inform. 22:117693512311546792023.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Parseghian CM, Napolitano S, Loree JM and
Kopetz S: Mechanisms of innate and acquired resistance to anti-EGFR
therapy: A review of current knowledge with a focus on rechallenge
therapies. Clin Cancer Res. 25:6899–6908. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Walens A, Lin J, Damrauer JS, McKinney B,
Lupo R, Newcomb R, Fox DB, Mabe NW, Gresham J, Sheng Z, et al:
Adaptation and selection shape clonal evolution of tumors during
residual disease and recurrence. Nat Commun. 11:50172020.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Fittall MW and Van Loo P: Translating
insights into tumor evolution to clinical practice: Promises and
challenges. Genome Med. 11:202019. View Article : Google Scholar : PubMed/NCBI
|
